Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + HAIC + PD-1 antibody for conversion therapy in unresectable advanced hepatocellular carcinoma
ChiCTR2200059297Phase 4Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Conversion success rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200059297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059297.